Stock 6576 FORESEE PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Foresee Pharmaceuticals Co., Ltd.

Equities

6576

TW0006576002

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-06-03 pm EDT 		5-day change 1st Jan Change
95.8 TWD +1.16% Intraday chart for Foresee Pharmaceuticals Co., Ltd. -0.10% -0.42%
May. 14 Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 03 Foresee Pharmaceuticals Co., Ltd. Appoints Chris Liang as Accounting Officer CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's "enterprise value to sales" ratio is among the highest in the world.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
FORESEE PHARMACEUTICALS CO., LTD. Stock Foresee Pharmaceuticals Co., Ltd.
-0.42% 398M -
MODERNA, INC. Stock Moderna, Inc.
+46.19% 56.65B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-6.14% 39.44B
B
LONZA GROUP AG Stock Lonza Group AG
+39.19% 39.03B
A
CELLTRION, INC. Stock Celltrion, Inc.
-6.65% 26.86B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.33% 26.75B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.78% 19.03B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.35% 12.28B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.18% 12.26B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.38% 12.04B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 6576 Stock
  4. Ratings Foresee Pharmaceuticals Co., Ltd.